FHA
HRTX icon

First Horizon Advisors’s Heron Therapeutics HRTX Stock Holding History

First Horizon Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,237
Closed -$6K – 2481
2022
Q3 		$6K Buy
1,237
+348
+39% +$1.36K ﹤0.01% 1702
2022
Q2 		$2K Buy
889
+833
+1,488% +$3.35K ﹤0.01% 2092
2022
Q1 		$0 Buy
+56
New +$410 ﹤0.01% 1969

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

First Horizon Advisors's HRTX Position: Q4 2022 in Review

First Horizon Advisors sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 1,237 shares — an estimated $6K sold.

First Horizon Advisors first reported a position in HRTX in Q1 2022 and held it in 3 quarters. The position peaked at $6K in Q3 2022. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • First Horizon Advisors reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • First Horizon Advisors sold 1,237 Heron Therapeutics shares in Q4 2022, an estimated $6K.
  • First Horizon Advisors first reported a position in Heron Therapeutics in Q1 2022 and held it in 3 quarters.
  • First Horizon Advisors's Heron Therapeutics position peaked at $6K in Q3 2022.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on First Horizon Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.